337 related articles for article (PubMed ID: 10657374)
1. Expression of matrix metalloproteinase-2 and -9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C.
Lichtinghagen R; Huegel O; Seifert T; Haberkorn CI; Michels D; Flemming P; Bahr M; Boeker KH
Clin Chem; 2000 Feb; 46(2):183-92. PubMed ID: 10657374
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase (MMP)-2, MMP-7, and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C.
Lichtinghagen R; Michels D; Haberkorn CI; Arndt B; Bahr M; Flemming P; Manns MP; Boeker KH
J Hepatol; 2001 Feb; 34(2):239-47. PubMed ID: 11281552
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic potential of serum matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as non-invasive markers of hepatic fibrosis in patients with HCV related chronic liver disease.
El-Gindy I; El Rahman AT; El-Alim MA; Zaki SS
Egypt J Immunol; 2003; 10(1):27-35. PubMed ID: 15719620
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C.
Boeker KH; Haberkorn CI; Michels D; Flemming P; Manns MP; Lichtinghagen R
Clin Chim Acta; 2002 Feb; 316(1-2):71-81. PubMed ID: 11750276
[TBL] [Abstract][Full Text] [Related]
5. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid.
Leroy V; Monier F; Bottari S; Trocme C; Sturm N; Hilleret MN; Morel F; Zarski JP
Am J Gastroenterol; 2004 Feb; 99(2):271-9. PubMed ID: 15046217
[TBL] [Abstract][Full Text] [Related]
6. Significance of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in chronic hepatitis C patients.
Badra G; Lotfy M; El-Refaie A; Obada M; Abdelmonem E; Kandeel S; Fathy A
Acta Microbiol Immunol Hung; 2010 Mar; 57(1):29-42. PubMed ID: 20350877
[TBL] [Abstract][Full Text] [Related]
7. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis.
Walsh KM; Timms P; Campbell S; MacSween RN; Morris AJ
Dig Dis Sci; 1999 Mar; 44(3):624-30. PubMed ID: 10080160
[TBL] [Abstract][Full Text] [Related]
8. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response.
Kasahara A; Hayashi N; Mochizuki K; Oshita M; Katayama K; Kato M; Masuzawa M; Yoshihara H; Naito M; Miyamoto T; Inoue A; Asai A; Hijioka T; Fusamoto H; Kamada T
J Hepatol; 1997 Mar; 26(3):574-83. PubMed ID: 9075665
[TBL] [Abstract][Full Text] [Related]
9. [Serum and urinary concentration of selected metalloproteinases and their tissue inhibitors in children with vesicoureteral reflux].
Taranta-Janusz K; Zoch-Zwierz W; Wasilewska A; Tenderenda E; Korzeniecka-Kozerska A
Pol Merkur Lekarski; 2010 Aug; 29(170):88-92. PubMed ID: 20842819
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of platelet derived growth factor-BB, transforming growth factor-beta1, matrix metalloproteinase-1, and tissue inhibitor of matrix metalloproteinase-1 in serum and peripheral blood mononuclear cells for hepatic fibrosis.
Zhang BB; Cai WM; Weng HL; Hu ZR; Lu J; Zheng M; Liu RH
World J Gastroenterol; 2003 Nov; 9(11):2490-6. PubMed ID: 14606082
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Matrix Metalloproteinase-2 (MMP-2) and -9 (MMP-9) and Their Tissue Inhibitors (TIMP-1 and TIMP-2) in Plasma from Patients with Neurodegenerative Dementia.
Tuna G; Yener GG; Oktay G; İşlekel GH; Kİrkalİ FG
J Alzheimers Dis; 2018; 66(3):1265-1273. PubMed ID: 30412498
[TBL] [Abstract][Full Text] [Related]
12. Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2.
Tayebjee MH; Lip GY; Blann AD; Macfadyen RJ
Thromb Res; 2005; 115(3):205-10. PubMed ID: 15617743
[TBL] [Abstract][Full Text] [Related]
13. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
Ulrich D; Hrynyschyn K; Pallua N
Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinases (MMP-2,9) and their tissue inhibitors (TIMP-1,2) as novel markers of stress response and atherogenesis in children with chronic kidney disease (CKD) on conservative treatment.
Musiał K; Zwolińska D
Cell Stress Chaperones; 2011 Jan; 16(1):97-103. PubMed ID: 20821177
[TBL] [Abstract][Full Text] [Related]
16. The Behavior of MMP-2, MMP-7, MMP-9, and Their Inhibitors TIMP-1 and TIMP-2 in Adenoma-Colorectal Cancer Sequence.
Barabás L; Hritz I; István G; Tulassay Z; Herszényi L
Dig Dis; 2021; 39(3):217-224. PubMed ID: 32961536
[TBL] [Abstract][Full Text] [Related]
17. Decreases in plasma MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios in uremic patients during hemodialysis.
Lu LC; Yang CW; Hsieh WY; Chuang WH; Lin YC; Lin CS
Clin Exp Nephrol; 2016 Dec; 20(6):934-942. PubMed ID: 26711243
[TBL] [Abstract][Full Text] [Related]
18. Significance of serum matrix metalloproteinases and their inhibitors on the antifibrogenetic effect of interferon-alfa in chronic hepatitis C patients.
Ninomiya T; Yoon S; Nagano H; Kumon Y; Seo Y; Kasuga M; Yano Y; Nakaji M; Hayashi Y
Intervirology; 2001; 44(4):227-31. PubMed ID: 11509885
[TBL] [Abstract][Full Text] [Related]
19. Serum metalloproteinases MMP-2, MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis.
Rysz J; Banach M; Stolarek RA; Mikhailidis DP; Cialkowska-Rysz A; Pokoca L; Piechota M; Baj Z
Int Urol Nephrol; 2011 Jun; 43(2):491-8. PubMed ID: 19953348
[TBL] [Abstract][Full Text] [Related]
20. Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis.
Lichtinghagen R; Seifert T; Kracke A; Marckmann S; Wurster U; Heidenreich F
J Neuroimmunol; 1999 Sep; 99(1):19-26. PubMed ID: 10496173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
